PubMed Health⌕ Search

Biomedical subjects

J N Walterspiel

Publications and source records attributed to J N Walterspiel.

At least 19 recordsLinked to original sources
PubMed1994

Secretory anti-Giardia lamblia antibodies in human milk: protective effect against diarrhea.

OBJECTIVE: To determine whether anti-Giardia lamblia secretory IgA (sIgA) antibodies in human milk protect infants from acquisition of or symptoms associated with Giardia infection. METHODS: One hundred ninety-seven Mexican mother/infant pairs were followed weekly from birth for diarrheal disease and feeding status. Infant stool specimens were collected weekly and were cultured for bacterial pathogens and tested for Giardia and rotavirus by enzyme-linked immunosorbent assay. Maternal milk samples were collected weekly for 1 month postpartum and monthly thereafter. To determine the protective effect of anti-Giardia sIgA in milk against infection and against diarrhea due to Giardia, milk samples from mothers of infected infants and appropriately matched controls were assayed for anti-Giardia sIgA by enzyme-linked immunosorbent assay. RESULTS: Asymptomatic, infected infants ingested significantly (P = .046) higher amounts of milk anti-Giardia sIgA compared with symptomatic, infected infants. However, milk anti-Giardia sIgA concentrations did not differ between Giardia-infected and noninfected infants. CONCLUSION: The amount of anti-Giardia sIgA in human milk was associated with prevention of symptoms of diarrhea due to Giardia, but not with acquisition of the organism.

Animals↗
PubMed1991

Design and performance of blanket heat shields for neonates.

BACKGROUND: Several designs of plastic blanket heat shields are in use. This study was done to compare different designs for their efficiency in reducing heat loss. METHODS: Four heat shield designs were tested by sequentially covering each of 14 infants (wt. 640-2,030 g) cared for under radiant warmers. The power consumption of the radiant warmers was measured as a surrogate for heat loss. All designs were tested for a total of 20 min on all infants. Results were calculated as percent change in power consumption from shield to shield. The most efficient design was further modified and evaluated in another group of 14 infants (wt. 700-1,180 g). RESULTS: The relative reductions in power consumption were: no shield (control) -0%, a plastic foil over the side rails: -17%, a single layer close to the infant but excluding the head: -34%, the same as double layer -37% and the most efficient one, a single layer covering the whole infant -42%. A modification of this design, tested in the second group of infants, reduced power consumption by 13% (95% CI -5.9/-19.7), (p less than 0.004) when compared to the single layer covering the whole infant. It was tucked under the connecting tubes to the ventilator. It also reduced the risk for displacement and allowed for the endotracheal tube to be suctioned without removing the blanket. CONCLUSION: Modifications of the design of heat shield blankets for infants resulted in significant increases in efficiency.

Bedding and Linens↗
PubMed1991

Comparative inactivation of isepamicin, amikacin, and gentamicin by nine beta-lactams and two beta-lactamase inhibitors, cilastatin and heparin.

This study was undertaken to compare the susceptibility to inactivation of isepamicin with amikacin and gentamicin when exposed to different beta-lactams, beta-lactamase inhibitors, and heparin. The aminoglycosides (5, 10, 20, and 50 micrograms/ml) were incubated in human serum with ampicillin, azlocillin, aztreonam, carbenicillin, ceftazidime, piperacillin, and ticarcillin (100 and 600 micrograms/ml) and with clavulanate, cilastatin, 1:1 imipenemcilastatin, oxacillin, and sulbactam (20 and 120 micrograms/ml) for 48 h at 37 degrees C. Aminoglycoside concentrations were measured by fluorescence polarization immunoassay (FPI) after 0, 8, and 48 h of incubation and by radial diffusion bioassay after 48 h of incubation. Each of the three aminoglycosides was also added to whole blood containing either heparin (100 U/ml) or 0.5% EDTA as a control and assayed after 6 h by FPI. The degree of inactivation of isepamicin by the beta-lactams was significantly less than that by amikacin (P less than 0.003) and gentamicin (P less than 0.0002) when determined by bioassay. Piperacillin, carbenicillin, and azlocillin produced the greatest amount of inactivation, and cilastatin and oxacillin produced the least. A similar pattern was observed when the degree of inactivation was measured by FPI. A significant difference in the degree of inactivation was noted between isepamicin and gentamicin (P less than 0.003 at 8 h and P less than 0.006 at 48 h) but not between isepamicin and amikacin (P greater than 0.7 at 8 h and P greater than 0.08 at 48 h). Aminoglycoside determinations by FPI were not influenced by the presence of heparin. In summary, isepamicin was found to be at least as stable as amikacin against inactivation by beta-lactam compounds and beta-lactamase inhibitors. Heparin (100 U/ml) did not influence aminoglycoside determinations by FPI.

Amikacin↗
PubMed1989

Adjunctive treatment with low-dose polymyxin B improves operant response rates and latency in infant rats with Haemophilus influenzae type b meningitis.

Polymyxin B given in conjunction with ampicillin protects infant rats against death from overwhelming Haemophilus influenzae type b infection. This study was undertaken to examine whether polymyxin B would mitigate the effects of brain damage caused by meningitis. Six- to 7-d-old Sprague-Dawley rats were infected subcutaneously into the nape with 10(7) cfu Haemophilus influenzae type b strain Eagan. This dose consistently caused bacteremia (1.2 X 10(5) cfu/mL) and meningitis (0.5 X 10(5) cfu/mL) in pilot studies. Twenty-four h after infection, all animals received intraperitoneal treatment consisting in either ampicillin alone (400 mg/kg X 4 q 3 h) repeated 12 h later, n = 15 or combined with polymyxin B (0.1 mg/kg/dose) n = 16. At age 2 mo, they were taken off ad libitum feeding and maintained at 80% of their wt. They were then conditioned to receive a food pellet by pressing a lever (continuous reinforcement). The next day, the time lapse between placement and pressing the lever for the first time was recorded (conditioned operant response or latency). Three wk later, the animals were put in the test chamber again and the time to press the lever (latency), as well as the time required to obtain 100 pellets (rate) were recorded. Animals who received polymyxin B had a significantly shorter reaction time; mean 34 s, SEM +/- 5.7 versus mean 88 s, SEM +/- 26.3, P less than or equal to 0.05 and performed significantly faster in obtaining 100 pellets; mean 925 s, SEM +/- 72.1 versus mean 1283 s, SEM +/- 126.3, p less than or equal to 0.02 (analysis of variance, Scheffé test).(ABSTRACT TRUNCATED AT 250 WORDS)

Ampicillin↗